Rethinking the role of long-acting atypical antipsychotics in the community setting

No abstract is available for this paper.

• Publication year

  2012

• Venue

  International Clinical Psychopharmacology

• Publication date

  2012-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/YIC.0b013e328357727aPMID 22859065
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia.

  2012influential reference
• Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia.

  2012cited by this paper
• Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS).

  2012influential reference
• Medication adherence and relapse in recent-onset psychosis.

  2011influential reference
• Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial

  2011influential reference
• Progressive pathology is functionally linked to the domains of language and emotion: meta-analysis of brain structure changes in schizophrenia patients

  2011cited by this paper
• Clinical utility of the risperidone formulations in the management of schizophrenia

  2011cited by this paper
• A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia.

  2011cited by this paper
• Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory.

  2011cited by this paper
• A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.

  2011influential reference
• Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials.

  2011influential reference
• Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching

  2011cited by this paper
• Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

  2011cited by this paper
• Long-Acting Risperidone and Oral Antipsychotics in Schizophrenia

  2011cited by this paper
• Dosing and Switching Strategies for Paliperidone Palmitate

  2011cited by this paper
• Proton Magnetic Resonance Spectroscopy and Illness Stage in Schizophrenia—A Systematic Review and Meta-Analysis

  2011cited by this paper
• Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology

  2011cited by this paper
• Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia.

  2011cited by this paper
• A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia

  2011cited by this paper
• Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia.

  2011cited by this paper
• Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE)

  2011influential reference
• Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia.

  2011influential reference
• Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists.

  2010cited by this paper
• Cost effectiveness of long-acting risperidone in Sweden

  2010cited by this paper
• Update on the use of MR for assessment and diagnosis of psychiatric diseases.

  2010influential reference
• A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

  2010cited by this paper
• Health professionals' attitudes to depot injection antipsychotic medication: a systematic review.

  2010cited by this paper
• How Law 180 in Italy has reshaped psychiatry after 30 years: past attitudes, current trends and unmet needs

  2010influential reference
• A Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of 3 Doses of Paliperidone Palmitate in Adults With Acutely Exacerbated Schizophrenia

  2010cited by this paper
• Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review

  2010influential reference
• The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

  2010cited by this paper
• How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed?

  2010cited by this paper
• Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention

  2010influential reference
• Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.

  2010influential reference
• Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis

  2010cited by this paper
• Are depot antipsychotics more coercive than tablets?

  2010cited by this paper
• Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial

  2010cited by this paper
• Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

  2010influential reference
• Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.

  2010influential reference
• Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study

  2010influential reference
• Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.

  2009cited by this paper
• Second-generation antipsychotic long-acting injections: Systematic review

  2009cited by this paper
• Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)

  2009influential reference
• An overview of the mental health system in Italy.

  2009cited by this paper
• Psychopharmacology and adverse effects of antipsychotic long-acting injections: A review

  2009cited by this paper
• Formulation optimization of long-acting depot injection of aripiprazole by using D-optimal mixture design.

  2009cited by this paper
• Antipsychotic long-acting injections: Prescribing practice in the UK

  2009cited by this paper
• Clinical guideline recommendations for antipsychotic long-acting injections

  2009influential reference
• First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: Systematic review of randomised controlled trials and observational studies

  2009cited by this paper
• Alcohol significantly lowers the seizure threshold in mice when co-administered with bupropion hydrochloride

  2008cited by this paper
• Structural and Organizational Determinants of Quality of Care in Patients With Schizophrenia in Italy

  2008cited by this paper
• Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood.

  2008cited by this paper
• Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting.

  2008cited by this paper
• Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection

  2008cited by this paper
• Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia

  2008cited by this paper
• Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.

  2008cited by this paper
• An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.

  2008cited by this paper
• Structural brain alterations at different stages of schizophrenia: a voxel-based morphometric study.

  2008cited by this paper
• Long-Acting Formulations of Atypical Antipsychotics

  2007influential reference
• Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study.

  2007cited by this paper
• Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study.

  2007cited by this paper
• Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome.

  2007cited by this paper
• Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 2: tratamento de longo prazo

  2006influential reference
• Brain volume in first-episode schizophrenia

  2006influential reference
• Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia

  2006cited by this paper
• Clinical Practice and Epidemiology in Mental Health Psychoeducational Intervention and Prevention of Relapse among Schizophrenic Disorders in the Italian Community Psychiatric Network

  2006cited by this paper
• Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

  2006cited by this paper
• Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia.

  2006cited by this paper
• Treatment of schizophrenia patients: comparing new-generation antipsychotics to each other

  2006cited by this paper
• Attitudes of psychiatrists toward antipsychotic depot medication.

  2006cited by this paper
• Why aren't depot antipsychotics prescribed more often and what can be done about it?

  2005cited by this paper
• Clinical practice guidelines. Treatment of schizophrenia.

  2005cited by this paper
• Hospitalization Rates in Patients During Long-Term Treatment With Long-Acting Risperidone Injection

  2005influential reference
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia

  2005cited by this paper
• Schizophrenia: core interventions in the treatment and management

  2005cited by this paper
• Pharmacological treatments for first-episode schizophrenia.

  2005cited by this paper
• Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.

  2005cited by this paper
• Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

  2005cited by this paper
• Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients

  2004cited by this paper
• Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.

  2004cited by this paper
• PHARMACOEPIDEMIOLOGY AND PRESCRIPTION Lorenza

  2004cited by this paper
• Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.

  2003cited by this paper
• Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia.

  2003cited by this paper
• The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia.

  2003cited by this paper
• Duration of untreated psychosis and outcome of schizophrenia: delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication.

  2003cited by this paper
• Clinical guidelines: Dosing and switching strategies for long-acting risperidone.

  2003cited by this paper
• Focus on psychiatry in Italy

  2002cited by this paper
• Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder.

  2002cited by this paper
• Does treatment delay in first-episode psychosis really matter?

  2002cited by this paper
• Pharmacy Data Identify Poorly Adherent Patients With Schizophrenia at Increased Risk for Admission

  2002cited by this paper
• An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.

  2002cited by this paper
• Systematic meta-review of depot antipsychotic drugs for people with schizophrenia

  2001cited by this paper
• Early intervention and a five year follow up in young adults with a short duration of untreated psychosis: ethical implications.

  2001cited by this paper
• Recovery from psychotic illness: A 15- and 25-year international follow-up study

  2001cited by this paper
• Systematic review of patient and nurse attitudes to depot antipsychotic medication

  2001cited by this paper
• Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder.

  1999cited by this paper
• Antipsychotic-induced weight gain: a comprehensive research synthesis.

  1999cited by this paper
• Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.

  1999cited by this paper
• Clinical practice guidelines.

  1999influential reference
• Utilization of neuroleptic drugs in Italian mental health services: a survey in Piedmont.

  1997cited by this paper

• Assessing the impact of an innovate behavioral health clinic: a retrospective cohort study

  2025cites this paper
• Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review

  2023cites this paper
• Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database

  2023cites this paper
• Second-Generation Antipsychotic Long-Acting Injection Reduced the Time of Restrictive Interventions in Patients With Schizophrenia

  2022cites this paper
• Comparative Effectiveness of Second Generation Long-acting Injectable Antipsychotics Based on Nationwide Database Research in Hungary: An Update

  2022cites this paper
• Observational Study of Long Acting Antipsychotic Prescription Patterns in Ourense Region, Spain (314,853 Inhabitants)

  2022cites this paper
• Guidance on the clinical understanding and use of long‐acting injectable antipsychotics in Schizophrenia: Hong Kong Consensus Statements

  2021cites this paper
• The Willingness of Community Psychiatric Management Physicians to Preferentially Recommend Long-Acting Injections in Beijing

  2021cites this paper
• Hospitalization Rates and Therapy Costs of German Schizophrenia Patients Who are Initiated on Long-Acting Injectable Medication: A Mirror-Image Study

  2020cites this paper
• Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics

  2020cites this paper
• The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia

  2019influential citation
• Evaluation of paliperidone palmitate long‐acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia

  2019influential citation
• Antipsicóticos inyectables de larga duración

  2019cites this paper
• The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia

  2019influential citation
• Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis

  2018cites this paper
• The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia

  2018cites this paper
• Paliperidone palmitate once‐every‐3‐months in adults with early illness schizophrenia

  2018cites this paper
• Suicide Prevention in Schizophrenia: Do Long-Acting Injectable Antipsychotics (LAIs) have a Role?

  2017cites this paper
• Gray matter volumes may predict the clinical response to paliperidone palmitate long-acting in acute psychosis: A pilot longitudinal neuroimaging study.

  2017cites this paper
• Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics

  2016cites this paper
• Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia

  2016cites this paper
• Gr upSM Treatment of Schizophrenia with Long-Acting Injectable Antipsychotics

  2016cites this paper
• Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia

  2016cites this paper
• Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia

  2015cites this paper
• Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia.

  2015cites this paper
• Pharmacological treatment , rehabilitative and psychosocial psychotherapy

  2015cites this paper
• Efficacy of LAI in first episode psychosis: an observational study--clinical reports.

  2015cites this paper
• Long-acting injection antipsychotic medications in the management of schizophrenia

  2015cites this paper
• Evidence-based Psychiatric Care: the Whys

  2015cites this paper
• Paliperidone Palmitate Depot in the Long-term Treatment of Psychotic Bipolar Disorder: A Case Series

  2015cites this paper
• Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders.

  2015cites this paper
• The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics

  2015cites this paper
• Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics.

  2015cites this paper
• Therapeutic continuity in the treatment of psychiatric disorders

  2015cites this paper
• Integrated treatment of schizophrenia

  2015cites this paper
• Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics

  2014cites this paper
• Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics

  2014cites this paper
• The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal

  2014influential citation
• A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea

  2014cites this paper
• Factors Associated With Antipsychotic Polypharmacy and High-Dose Antipsychotics Among Individuals Receiving Compulsory Treatment in the Community

  2014cites this paper
• Barriers to Utilizing Long-Acting Injectable Antipsychotic Medications

  2014cites this paper
• Efficacy and safety of long acting injectable atypical antipsychotics: a review.

  2013cites this paper
• Optimizing Outcomes in Schizophrenia: Long-acting Depots and Long-term Treatment

  2012cites this paper